HMG-CoA reductase is a potential therapeutic target for migraine: a mendelian randomization study
Qu K., Li MX., Yu P., Wu BH., Shi M., Dong M., Palotie A., Pressman A., Belin AC., Bjornsdottir A., van den Maagdenberg AMJM., Harder AVE., Winsvold BS., Müller-Myhsok B., Cormand B., Ran C., Northover C., Kubisch C., van Duijn C., Nyholt DR., Chasman DI., Posthuma D., Lessel D., Boomsma DI., Hämäläinen E., Kristoffersen ES., Cuenca-Leon E., Davey-Smith G., Terwindt GM., Sigurdardottir GR., Bjornsdottir G., Hautakangas H., Stefansson H., de Boer I., Kaprio J., Olesen J., Zwart JA., Stefansson K., Ligthart L., Launer L., Pedersen LM., Kogelman LJA., Griffiths LR., Ikram MA., Wessman M., Kaunisto M., Hrafnsdottir MG., Hiekkala M., Järvelin MR., Dichgans M., Pirinen M., Kallela M., Kurki M., Chalmer MA., Pedersen N., Sveinsson OA., Raitakari O., Gormley P., Pozo-Rosich P., Palta P., Malik R., Kajanne R., Børte S., Magnusson SH., Lehtimäki T., Hansen TF., Thorgeirsson TE., Freilinger T., Kurth T., Esko T., Anttila V., Artto V.
Statins are thought to have positive effects on migraine but existing data are inconclusive. We aimed to evaluate the causal effect of such drugs on migraines using Mendelian randomization. We used four types of genetic instruments as proxies for HMG-CoA reductase inhibition. We included the expression quantitative trait loci of the HMG-CoA reductase gene and genetic variation within or near the HMG-CoA reductase gene region. Variants were associated with low-density lipoprotein cholesterol, apolipoprotein B, and total cholesterol. Genome-wide association study summary data for the three lipids were obtained from the UK Biobank. Comparable data for migraine were obtained from the International Headache Genetic Consortium and the FinnGen Consortium. Inverse variance weighting method was used for the primary analysis. Additional analyses included pleiotropic robust methods, colocalization, and meta-analysis. Genetically determined high expression of HMG-CoA reductase was associated with an increased risk of migraines (OR = 1.55, 95% CI 1.30–1.84, P = 6.87 × 10−7). Similarly, three genetically determined HMG-CoA reductase-mediated lipids were associated with an increased risk of migraine. These conclusions were consistent across meta-analyses. We found no evidence of bias caused by pleiotropy or genetic confounding factors. These findings support the hypothesis that statins can be used to treat migraine.